• Therapy areas
  • Products
  • Careers
  • About us
  • Patient help
  • Healthcare professionals
  • Media & Investors
  • Contact us

Latest news

{{'Mon, 16 Nov 2026 17:00:00 -0500' | dateFormatUsFilter}}

Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®

Read more

{{'Mon, 16 Nov 2026 10:00:00 -0500' | dateFormatUsFilter}}

Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine

Read more

{{'Sun, 15 Nov 2026 08:00:00 -0500' | dateFormatUsFilter}}

Novo’s CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026

Read more

News archive

Latest on compounded and counterfeit products and other important information about semaglutide.

Visit semaglutide.com

Careers


NOVO USA

800 Scudders Mill Road
Plainsboro, NJ 08536
Tel: 1-609-987-5800

 

Transparency in Employee Health Coverage:

Aetna
United Healthcare

Helpful links

  • Contact us
  • Copyright
  • Report a side effect or product complaint

Follow us

  • Instagram
  • Facebook
  • X (Twitter)
  • TikTok
  • LinkedIn

Other offices

Select location
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Privacy Policy
Consumer Health Data Privacy Notice
Cookie Notice
Cookie Settings
Your Privacy Choices